Profile data is unavailable for this security.
About the company
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
- Revenue in USD (TTM)2.00bn
- Net income in USD-332.08m
- Incorporated2003
- Employees2.10k
- LocationAlnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
- Phone+1 (617) 551-8200
- Fax+1 (617) 551-8101
- Websitehttps://www.alnylam.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
United Therapeutics Corporation | 2.50bn | 1.05bn | 15.00bn | 1.17k | 16.01 | 2.80 | 13.57 | 6.00 | 21.13 | 21.13 | 50.24 | 120.76 | 0.3891 | 2.50 | 11.31 | 2,138,956.00 | 16.36 | 10.38 | 18.03 | 11.27 | 88.87 | 91.47 | 42.05 | 29.25 | 3.64 | -- | 0.101 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
ICON PLC | 8.23bn | 683.12m | 26.79bn | 41.10k | 39.25 | 2.84 | 21.04 | 3.25 | 8.24 | 8.24 | 99.33 | 114.08 | 0.4795 | -- | 2.92 | 200,291.60 | 3.98 | 3.93 | 4.80 | 4.80 | 29.67 | 28.91 | 8.30 | 7.37 | -- | 3.48 | 0.2706 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Alnylam Pharmaceuticals, Inc. | 2.00bn | -332.08m | 29.71bn | 2.10k | -- | -- | -- | 14.83 | -2.71 | -2.71 | 15.78 | -1.73 | 0.5552 | 2.85 | 11.67 | 953,969.10 | -9.20 | -26.56 | -11.86 | -32.77 | 83.95 | 83.66 | -16.58 | -94.26 | 3.07 | -1.37 | 1.27 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
Iqvia Holdings Inc | 15.16bn | 1.42bn | 43.69bn | 88.00k | 31.09 | 6.51 | 16.99 | 2.88 | 7.71 | 7.71 | 82.07 | 36.83 | 0.5781 | -- | 4.74 | 174,195.40 | 5.44 | 3.24 | 7.26 | 4.07 | 35.10 | 34.32 | 9.40 | 6.03 | -- | 3.27 | 0.6638 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 12.79m | 10.11% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 11.70m | 9.25% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.43m | 7.45% |
Wellington Management Co. LLPas of 31 Mar 2024 | 7.02m | 5.55% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.11m | 4.83% |
Baillie Gifford & Co.as of 30 Jun 2024 | 6.03m | 4.77% |
Dodge & Coxas of 31 Mar 2024 | 3.81m | 3.01% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 3.65m | 2.89% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.59m | 2.84% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.19m | 2.52% |